Literature DB >> 23092658

Streptococcus pneumoniae serotype 15A in psychiatric unit, Rhode Island, USA, 2010-2011.

Katherine Fleming-Dutra1, Chukwuma Mbaeyi, Ruth Link-Gelles, Nicole Alexander, Alice Guh, Elizabeth Forbes, Bernard Beall, Jonas M Winchell, Maria da Gloria Carvalho, Fabiana Pimenta, Maja Kodani, Cindy Vanner, Hilary Stevens, Diane Brady, Mardea Caulcrick-Grimes, Utpala Bandy, Matthew R Moore.   

Abstract

During a pneumococcal disease outbreak in a pediatric psychiatric unit in a hospital in Rhode Island, USA, 6 (30%) of 20 patients and staff were colonized with Streptococcus pneumoniae serotype 15A, which is not included in pneumococcal vaccines. The outbreak subsided after implementation of antimicrobial drug prophylaxis and enhanced infection control measures.

Entities:  

Mesh:

Year:  2012        PMID: 23092658      PMCID: PMC3559171          DOI: 10.3201/eid1811.120454

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Streptococcus pneumoniae, or pneumococcus, causes an estimated 4 million illnesses in the United States annually (). Pneumococcal disease outbreaks often occur in closed settings such as childcare facilities and hospitals. Control measures include vaccination, antimicrobial drug prophylaxis, and infection control (). On January 26, 2011, the Rhode Island Department of Health was notified of 2 cases of invasive pneumococcal disease (IPD) and 2 cases of pneumonia that were associated with a unit (Unit 1) in a pediatric psychiatric hospital that had unusual infection control challenges. We investigated the outbreak to confirm the etiologic agent and prevent disease transmission.

The Study

Children who have developmental disabilities and aggressive or self-injurious behavior are treated in Unit 1. Inpatient capacity is 17, and <5 outpatients are sometimes present during the day for group and individual therapy. The unit employs >100 staff members. Patients require constant supervision and intensive help with activities of daily living. At the beginning of this investigation, we established outbreak case definitions. We defined confirmed pneumococcal disease as IPD (isolation of S. pneumoniae from a normally sterile site such as blood) or noninvasive (laboratory confirmation of S. pneumoniae from a nonsterile site in the setting of a compatible clinical illness, such as isolation from ear drainage samples from a patient with otitis media). We defined confirmed pneumonia as pneumonia diagnosed by a clinician, using chest radiographs confirmed as showing pneumonia by a radiologist. We defined suspected pneumonia as pneumonia diagnosed by a clinician with no radiologic studies obtained. Cases occurred in Unit 1 staff, patients, and visitors during the study period. We maintained active surveillance through May 1, but no cases occurred after February 23. To identify risk factors for pneumococcal disease (,), we abstracted medical records of all Unit 1 patients (n = 30) during November 1, 2010–January 30, 2011. Unit 1 staff members completed questionnaires about respiratory illnesses experienced during December–February. The hospital informed families of then-current Unit 1 patients of the outbreak. Family members or visitors who reported illness were interviewed. All pertinent medical records were reviewed. We collected available clinical specimens and conducted a survey to identify respiratory pathogens carried by patients and staff (Figure 1). We collected nasopharyngeal and oropharyngeal calcium alginate swab specimens from then-current Unit 1 patients (n = 16) and staff with ongoing respiratory symptoms (n = 4) during January 29–February 2. For pneumococcal carriage, swab specimens were processed as described (,). Three pneumococcal isolates were recovered (2 from blood, 1 from ear drainage samples). Swab specimens and isolates underwent specific real-time PCR that targeted the lytA gene (), PCR-based serotyping (,), and multilocus sequence type determination (). Antibacterial drug susceptibility testing was performed by using broth microdilution (). Additional swabs stored in viral transport media were tested by solid-phase real-time PCR on TaqMan Array Cards (Life Technologies, Carlsbad, CA, USA), for 20 additional respiratory pathogen targets ().
Figure 1

Respiratory pathogen carriage survey related to Streptococcus pneumoniae serotype 15A outbreak in a pediatric psychiatric hospital, Rhode Island, USA, December 25, 2010–January 31, 2011, performed on Unit 1 patients (n = 16) and symptomatic staff (n = 4) during January 29–February 2. No visitors were screened for respiratory pathogen carriage. Nasopharyngeal (NP) and oropharyngeal (OP) swab specimens were taken from each participant. TaqMan Array Card (TAC) used to test for influenza A (H1 and H3) and B, respiratory syncytial virus, human parainfluenza viruses 1–3, human metapneumovirus, rhinovirus, enterovirus, parechovirus, adenovirus, Legionella species, Haemophilus influenzae, Streptococcus pyogenes, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis. Asterisk indicates other pneumococcal serotypes identified in 3 persons, including 11A/D, 20, 34, and serotypes that were nontypeable by real-time PCR: 1, 2, 3, 4, 5, 6A/B/C, 6C, 7F/7A, 9V/9A, 11A/11D, 12F/(12A/44/46), 14, 15A/15F, 16F, 18/(18A/18B/18C/18F), 19A, 19F, 22F/22A, 23A, 23F, 33F/33A/37.

Respiratory pathogen carriage survey related to Streptococcus pneumoniae serotype 15A outbreak in a pediatric psychiatric hospital, Rhode Island, USA, December 25, 2010–January 31, 2011, performed on Unit 1 patients (n = 16) and symptomatic staff (n = 4) during January 29–February 2. No visitors were screened for respiratory pathogen carriage. Nasopharyngeal (NP) and oropharyngeal (OP) swab specimens were taken from each participant. TaqMan Array Card (TAC) used to test for influenza A (H1 and H3) and B, respiratory syncytial virus, human parainfluenza viruses 1–3, human metapneumovirus, rhinovirus, enterovirus, parechovirus, adenovirus, Legionella species, Haemophilus influenzae, Streptococcus pyogenes, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis. Asterisk indicates other pneumococcal serotypes identified in 3 persons, including 11A/D, 20, 34, and serotypes that were nontypeable by real-time PCR: 1, 2, 3, 4, 5, 6A/B/C, 6C, 7F/7A, 9V/9A, 11A/11D, 12F/(12A/44/46), 14, 15A/15F, 16F, 18/(18A/18B/18C/18F), 19A, 19F, 22F/22A, 23A, 23F, 33F/33A/37. Twenty patients resided on Unit 1 during December 25, 2010–January 31, 2011 (Table 1). Among Unit 1 patients, staff, and visitors, the following cases were identified: 3 confirmed pneumococcal disease, 6 confirmed pneumonia, and 2 suspected pneumonia (Figure 2). Three case-patients were hospitalized (2 with IPD, 1 with confirmed pneumonia). Among the 20 patients, the cases of 5 (attack rate 25%) met an outbreak case definition (Table 2). In addition, 1 staff member had IPD, 1 had confirmed pneumonia, and 1 had suspected pneumonia (Table 2, attack rate <3%). These staff members provided direct care to all Unit 1 patients. Three visitors had confirmed pneumonia. Adults (3 staff and 3 visitors) who became ill during the outbreak and for whom ages were available (5 of 6) ranged in age from 27 to 56 years.
Table 1

Characteristics of 20 psychiatric unit patients during Streptococcus pneumoniae serotype 15A outbreak, Rhode Island, USA, December 25, 2010–January 31, 2011

CharacteristicNo. (%) patients
Male sex14 (70.0)
Median age, y (range)13 (4–24)
Race
White16 (80.0)
Black4 (20.0)
Other/unknown0
Underlying medical conditions
Asthma*6 (30.0)
Chronic heart disease2 (10.0)
Other risk factors for pneumococcal infection†0
Median length of stay, days on Unit 1 as of January 30, 2011 (range)71 (1–706)
Receiving systemic antimicrobial drugs during January for illness unrelated to outbreak1 (5.0)
No. patients on Unit 1 as of January 30, 2011
Current in-patient15 (75.0)
Day program patient‡1 (20.0)
Discharged (since December 25, 2010)4 (5.0)

*None were treated with systemic steroids (i.e., none had an indication for vaccine) (,).
†Includes chronic lung disease (other than asthma), diabetes mellitus, cerebrospinal fluid leaks, cochlear implant, systemic steroid use, sickle cell disease, congenital or acquired asplenia, HIV infection, chronic renal failure, nephritic syndrome or kidney disease with dialysis, bone-marrow or organ transplant, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemia, lymphoma, and Hodgkin disease (,).
‡Day program patients were treated in Unit 1 during the day and returned home to stay overnight with their families.

Figure 2

Epidemic curve of Streptococcus pneumoniae outbreak in a pediatric psychiatric hospital, Rhode Island, USA, December 25, 2010–January 31, 2011, for invasive pneumococcal disease, noninvasive pneumococcal disease, confirmed pneumonia, and suspected pneumonia. *Staff members; †family members.

Table 2

Cases, clinical isolates, and results of pneumococcal carriage and respiratory pathogen survey associated with Streptococcus pneumoniae serotype 15A outbreak, Rhode Island, USA, December 25, 2010–January 31, 2011*

Case statusCase no.Onset dateCulture date, specimen and resultChest imaging resultsTreatmentOutcomeCarriageSeroOther pathogens by TAC†
IPDS1Jan 9Jan 14, blood, S. pneumoniae 15ARight upper lobe pneumoniaMoxifloxacinRecNegNeg
IPDP1Jan 11Jan 25, blood, S. pneumoniae 15ANegativeCeftriaxoneRecPos15ARhinovirus, adenovirus
Noninvasive pneumococcal diseaseP2Jan 2Jan 28, otorrhea, S. pneumoniae 15ACefuroxime, topical ofloxacinRecPos15A Mycoplasma pneumoniae
Confirmed pneumoniaP3Jan 2Left lower lobe pneumoniaAmoxicillin/ clavulanate, azithromycinRecPosNT‡Rhinovirus
Confirmed pneumoniaS2Jan 5Left upper lobe pneumoniaAmoxicillin/ clavuanate, ciprofloxacinRecNSNS
Confirmed pneumoniaV1Jan 15Right basilar pneumoniaMoxifloxacinRecNSNS
Confirmed pneumoniaP4Jan 18Right lower lobe pneumoniaCeftriaxone, ampicillin, amoxicillinRecNeg M. pneumoniae
Confirmed pneumoniaV2Feb 4Left lower lobe pneumoniaDoxycycline, levofloxacinRecNSNS
Confirmed pneumonia§V3Feb 23Left lower lobe pneumoniaUnkUnkNSNS
Suspected pneumoniaS3Jan 11AzithromycinRecNSNS
Suspected pneumoniaP5Jan 13ClindamycinRecNegNeg
Non-caseP6Neg S. pyogenes
Non-caseP7NegAdenovirus
Non-caseP8NegNeg
Non-caseP9Pos34 S. pyogenes
Non-caseP10NegNeg
Non-caseP11Pos15AEnterovirus
Non-caseP12Pos15ANeg
Non-caseP13Pos11 A/D, 20 S. pyogenes
Non-caseP14NegNeg
Non-caseP15Pos15ARhinovirus, M. pneumoniae
Non-caseP16Pos15A M. pneumoniae
Non-caseS4NegRhinovirus
Non-caseS5NegNeg
Non-caseS6Neg S. pyogenes

*Sero, serotype; TAC, TaqMan Array Card; IPD, invasive pneumococcal disease; S, staff; rec, recovered; neg, negative; P, patient; pos, positive; NS, no carriage screen; V, visitor; NT, nontypeable; Unk, unknown.
†TAC used to test for influenza viruses A (H1 and H3) and B, respiratory syncytial virus, human parainfluenza viruses 1–3, human metapneumovirus, rhinovirus, enterovirus, parechovirus, adenovirus, 
‡NT by real-time PCR (for serotypes: 1, 2, 3, 4, 5, 6A/B/C, 6C, 7F/7A, 9V/9A, 11A/11D, 12F/(12A/44/46), 14, 15A/15F, 16F, 18/(18A/18B/18C/18F), 19A, 19F, 22F/22A, 23A, 23F, 33F/33A/37).
§Refused further involvement with investigation.

*None were treated with systemic steroids (i.e., none had an indication for vaccine) (,).
†Includes chronic lung disease (other than asthma), diabetes mellitus, cerebrospinal fluid leaks, cochlear implant, systemic steroid use, sickle cell disease, congenital or acquired asplenia, HIV infection, chronic renal failure, nephritic syndrome or kidney disease with dialysis, bone-marrow or organ transplant, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemia, lymphoma, and Hodgkin disease (,).
‡Day program patients were treated in Unit 1 during the day and returned home to stay overnight with their families. Epidemic curve of Streptococcus pneumoniae outbreak in a pediatric psychiatric hospital, Rhode Island, USA, December 25, 2010–January 31, 2011, for invasive pneumococcal disease, noninvasive pneumococcal disease, confirmed pneumonia, and suspected pneumonia. *Staff members; †family members. *Sero, serotype; TAC, TaqMan Array Card; IPD, invasive pneumococcal disease; S, staff; rec, recovered; neg, negative; P, patient; pos, positive; NS, no carriage screen; V, visitor; NT, nontypeable; Unk, unknown.
†TAC used to test for influenza viruses A (H1 and H3) and B, respiratory syncytial virus, human parainfluenza viruses 1–3, human metapneumovirus, rhinovirus, enterovirus, parechovirus, adenovirus, 
‡NT by real-time PCR (for serotypes: 1, 2, 3, 4, 5, 6A/B/C, 6C, 7F/7A, 9V/9A, 11A/11D, 12F/(12A/44/46), 14, 15A/15F, 16F, 18/(18A/18B/18C/18F), 19A, 19F, 22F/22A, 23A, 23F, 33F/33A/37).
§Refused further involvement with investigation. All 3 clinical isolates were identified as S. pneumoniae serotype 15A, sequence type 63, (Table 2) with matching antimicrobial drug susceptibility patterns. Nine (45%) of 20 persons tested carried pneumococcus; of those, 6 (30%) carried serotype 15A. Rhinovirus, Streptococcus pyogenes, and Mycoplasma pneumoniae were additional pathogens most frequently identified by using TaqMan Array Cards (Figure 1, Table 2). We assessed Unit 1 infection control practices; in particular, for staff compliance with hand and respiratory hygiene. The hand hygiene audit revealed that staff members had performed hand hygiene in 4 (24%) of 17 instances before patient contact and 11 (79%) of 14 times after patient contact, for an overall compliance of 15 (48%) of 31 opportunities. In addition,, supplies (e.g., gloves) were kept in locked cabinets because of safety concerns. Staff reported that patients, because of their developmental delays, were often unable to appropriately manage their respiratory secretions. The presence of 6 carriers of serotype 15A on Unit 1 during the carriage survey indicated the potential for continued transmission and disease. The hospital mandated hand and respiratory hygiene training for all Unit 1 staff, administered during February 4–8. We recommended high-dose amoxicillin prophylaxis (90 mg/kg/day divided into 2 doses, maximum of 1,000 mg, for 5 days) for all Unit 1 patients, which began on February 7. After control measures were fully implemented, 1 case of pneumonia was confirmed in a patient’s parent on February 23, but the etiology was not identified. No additional cases occurred among Unit 1 patients and staff members during the subsequent 3 months.

Conclusions

Laboratory and epidemiologic evidence indicates that an outbreak of S. pneumoniae serotype 15A infection occurred on Unit 1. Increased transmission opportunities likely resulted from infection control challenges in the unit. Because serotype 15A is not included in any current pneumococcal vaccine, we used antimicrobial drug prophylaxis as an immediate intervention to reduce transmission. However, infection control was the critical long-term control measure. We modified acute-care hospital infection control practices for the unique environment of Unit 1, such as scheduling hand hygiene sessions every 2–3 hours for all patients, rather than expecting patients to understand when to perform hand hygiene. Furthermore, other respiratory pathogens were present on Unit 1, which could have contributed to disease and facilitated pneumococcal transmission by increasing nasopharyngeal colonization (). The same infection control lapses that led to the S. pneumoniae serotype 15A outbreak likely led to transmission of these respiratory pathogens. Since the introduction of the 7-valent pneumococcal conjugate vaccine, nasopharyngeal carriage of serotype 15A has increased (). Among Massachusetts children 3 months–7 years of age, serotype 15A carriage prevalence was 4% in 2007 (), compared with 30% in this outbreak. Since the introduction of the 7-valent pneumococcal conjugate vaccine, serotype15A sequence type 63 has also caused an increasing proportion of penicillin-nonsusceptible IPD in the United States (). The sequence type and antimicrobial drug susceptibilities of the serotype 15A strain from this outbreak are characteristic of a single, internationally disseminated serotype 15A strain (). No other increases in IPD or serotype 15A were detected by the Rhode Island Department of Health during this period, indicating that the outbreak was restricted to Unit 1. This investigation had several limitations. First, diagnostic tests were performed at the discretion of treating clinicians, and specific diagnostic testing was not performed for most pneumonia case-patients. In addition, we used TaqMan Array Cards <3 weeks after symptom onset, which decreased our ability to detect all bacterial and viral co-factors that possibly contributed to this outbreak. Because of the small size of the patient cohort, statistical tests would not have power to assess risk factors for pneumococcal disease or carriage. Finally, we did not assess the knowledge of hand hygiene among staff after the training to evaluate its effectiveness. In conclusion, this outbreak was associated with S. pneumoniae serotype 15A, a serotype not included in available pneumococcal vaccines. The outbreak subsided after patients received antimicrobial drug prophylaxis. The hospital instituted a hand hygiene monitoring program in response to our recommendations and enhanced infection control practices were implemented, especially careful adherence to hand and respiratory hygiene. Hand and respiratory hygiene training and monitoring are critical for infection control in units that serve patients with special cognitive needs.
  12 in total

Review 1.  Effective management in clusters of pneumococcal disease: a systematic review.

Authors:  Marina Basarab; Chikwe Ihekweazu; Robert George; Richard Pebody
Journal:  Lancet Infect Dis       Date:  2011-02       Impact factor: 25.071

2.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.

Authors:  Robert E Gertz; Zhongya Li; Fabiana C Pimenta; Delois Jackson; Billie A Juni; Ruth Lynfield; James H Jorgensen; Maria da Gloria Carvalho; Bernard W Beall
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

3.  Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates.

Authors:  Rekha Pai; Robert E Gertz; Bernard Beall
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Authors:  Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

5.  Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes.

Authors:  Maria da Gloria Carvalho; Fabiana C Pimenta; Delois Jackson; Alexis Roundtree; Yusra Ahmad; Eugene V Millar; Katherine L O'Brien; Cynthia G Whitney; Adam L Cohen; Bernard W Beall
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

6.  Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies.

Authors:  K L O'Brien; M A Bronsdon; R Dagan; P Yagupsky; J Janco; J Elliott; C G Whitney; Y H Yang; L G Robinson; B Schwartz; G M Carlone
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

7.  Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-09-03       Impact factor: 17.586

8.  Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Pekka Nuorti; Cynthia G Whitney
Journal:  MMWR Recomm Rep       Date:  2010-12-10

9.  Healthcare utilization and cost of pneumococcal disease in the United States.

Authors:  Susan S Huang; Kristen M Johnson; G Thomas Ray; Peter Wroe; Tracy A Lieu; Matthew R Moore; Elizabeth R Zell; Jeffrey A Linder; Carlos G Grijalva; Joshua P Metlay; Jonathan A Finkelstein
Journal:  Vaccine       Date:  2011-03-11       Impact factor: 3.641

Review 10.  Respiratory viruses predisposing to bacterial infections: role of neuraminidase.

Authors:  Ville T Peltola; Jonathan A McCullers
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

View more
  7 in total

1.  First report of an outbreak of pneumonia caused by Streptococcus pneumoniae serotype 6A.

Authors:  Karla Prebil; Bojana Beović; Metka Paragi; Katja Seme; Tamara Kastrin; Blanka Kores Plesničar; Bojana Petek; Žiga Martinčič
Journal:  Wien Klin Wochenschr       Date:  2015-10-14       Impact factor: 1.704

2.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era.

Authors:  Chiara Mameli; Valentina Fabiano; Laura Daprai; Giorgio Bedogni; Marino Faccini; Maria Laura Garlaschi; Francesca Penagini; Dario Dilillo; Erminio Torresani; Maria Gramegna; Gian Vincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Trend of invasive pneumococal disease (IPD) in a South Western, Nigerian hospital.

Authors:  Motayo Babatunde Olanrewaju; Akingbade Olusola; Nwadike Victor; Shobayo Olabode; Ogiogwa Joseph; Akinduti Akiniyi; Okonko Iheanyi
Journal:  Pan Afr Med J       Date:  2016-03-28

Review 5.  Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review.

Authors:  Paul N Zivich; John D Grabenstein; Sylvia I Becker-Dreps; David J Weber
Journal:  Pneumonia (Nathan)       Date:  2018-11-05

6.  Call to action on world pneumonia day.

Authors:  Rana Hajjeh; Cynthia G Whitney
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

7.  Antibiotic Resistance and Molecular Biological Characteristics of Non-13-Valent-Pneumococcal Conjugate Vaccine Serogroup 15 Streptococcus pneumoniae Isolated From Children in China.

Authors:  Wei Shi; Qianqian Du; Lin Yuan; Wei Gao; Qing Wang; Kaihu Yao
Journal:  Front Microbiol       Date:  2022-01-05       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.